Blueprint Medicines is a patient-driven oncology company developing highly selective kinase inhibitors for genomically defined cancer subsets. Led by a management team and advisors with world-renowned expertise in cancer genomics, drug discovery and clinical oncology, Blueprint has developed a platform that combines genomics with a novel library of kinase inhibitors, enabling Blueprint to rapidly develop potent highly selective compounds against clear genomic driver targets.
January 8, 2015
Blueprint Medicines to Present at the 33rd Annual J.P. Morgan Healthcare Conference … [Read More...]
December 8, 2014
Blueprint Medicines Debuts Comprehensive Preclinical Data Set on First Selective Drug for … [Read More...]